Products
Ecromeximab Biosimilar Monoclonal Antibody (GD3) for Research
Cat No.: GMP-Bios-INN-807
Anti-ganglioside GD3 therapeutic antibody (Pre-made Ecromeximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-807-1mg | 1mg | 3090 |
| GMP-Bios-INN-807-10mg | 10mg | |
| GMP-Bios-INN-807-100mg | 100mg | |
| GMP-Bios-INN-807-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ecromeximab Biosimilar, Whole Mab: Anti-Ganglioside Gd3 therapeutic antibody |
| INN Name | Ecromeximab |
| Target | ganglioside GD3 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Ludwig Institute for Cancer Research (New York NY USA) / Life Science Pharmaceuticals (LSP) (Darien CT USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | YB2/0 cell line: low fucosylation |
